US Patent 8,557,834: Scope, Claims, Expiration, and Patent Landscape for FG-2216
US Patent 8,557,834 protects a narrow therapeutic use of N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, commonly identified as FG-2216, for treating anemia associated with renal disease. The patent does not claim the compound broadly, a pharmaceutical composition, a dosage regimen, or a manufacturing process. Claim 1 covers the free compound. Claim 2 covers the compound and its pharmaceutically acceptable salts.
Because FG-2216 has not obtained FDA approval as a marketed drug, US 8,557,834 does not create a conventional Orange Book or Paragraph IV pathway. Commercial risk would instead arise from direct method infringement, induced infringement, use of a related product, or enforcement of other composition, formulation, manufacturing, or disease-treatment patents in the same family or portfolio.
What drug and therapeutic target does US 8,557,834 cover?
The claimed molecule is FG-2216, a small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI. HIF-PH inhibition increases HIF signaling and can stimulate endogenous erythropoietin production and iron-utilization pathways.
The patent’s therapeutic indication is anemia associated with renal disease. The language is consistent with chronic kidney disease-associated anemia, including anemia arising from impaired endogenous erythropoietin production. The claims do not expressly limit treatment to dialysis patients, nondialysis patients, a particular stage of chronic kidney disease, or a particular hemoglobin concentration.
Compound identity
| Item |
Description |
| Claimed active |
N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine |
| Common development identifier |
FG-2216 |
| Drug class |
HIF prolyl hydroxylase inhibitor |
| Therapeutic use |
Treatment of anemia associated with renal disease |
| Dosage form in claims |
Not specified |
| Route of administration |
Not specified |
| Patient population |
Human patients |
| Required disease relationship |
Anemia associated with renal disease |
The claim language does not require that the compound be administered alone. A regimen that includes iron supplementation, dialysis, erythropoiesis-stimulating agents, or other supportive therapy could still fall within the claims if the claimed compound is administered for the claimed purpose.
What do the claims of US 8,557,834 cover?
Claim 1: free compound method claim
Claim 1 covers:
A method of treating anemia associated with renal disease in a human by administering the specified FG-2216 compound.
The material limitations are:
- A human patient.
- Anemia.
- An association between the anemia and renal disease.
- Administration of the specified chemical compound.
- Treatment intent or therapeutic use.
Claim 1 is a method-of-treatment claim rather than a composition-of-matter claim. It does not prevent every manufacture, sale, or possession of FG-2216. It is directed to performance of the claimed medical method.
The claim does not require:
- A specified dose.
- A specified frequency.
- Oral, intravenous, subcutaneous, or other administration.
- A defined treatment duration.
- A particular formulation.
- A demonstrated increase in hemoglobin.
- A specific chronic kidney disease stage.
- Dialysis.
- Failure of prior erythropoiesis-stimulating-agent therapy.
- A specific erythropoietin level.
Claim 2: compound and pharmaceutically acceptable salts
Claim 2 covers administration of the same active compound or a pharmaceutically acceptable salt.
The salt language expands the chemical form covered by the claim. It is relevant where a commercial product is developed as a salt rather than as the neutral parent compound. Depending on claim construction, the phrase “or a pharmaceutically acceptable salt thereof” may also make Claim 2 overlap substantially with Claim 1 because the free compound is the primary chemical form.
The claim does not separately define:
- The counterion.
- Crystal form.
- Solvate or hydrate status.
- Particle size.
- Polymorph.
- Excipient system.
- Release profile.
Those features could be protected by separate formulation or solid-state claims, but they are not required by the two claims provided.
How narrow is the patent scope?
US 8,557,834 is narrow in chemical and therapeutic scope but potentially meaningful within its specific field.
Chemical scope
The claims identify one defined pyrimidinedione compound. They do not expressly cover:
- Other HIF-PH inhibitors.
- Structural analogs.
- Prodrugs.
- Metabolites.
- Deuterated versions.
- Isotopically labeled compounds.
- Different heterocyclic cores.
- Substituted analogs outside the named structure.
A competitor using roxadustat, daprodustat, vadadustat, molidustat, enarodustat, or another distinct HIF-PHI would not ordinarily fall within these claims solely because the competing drug has the same pharmacological mechanism.
Indication scope
The indication is broader than a claim limited to a particular renal-disease stage or dialysis setting. “Anemia associated with renal disease” could cover multiple renal disease populations if the factual and medical relationship is established.
The claim is narrower than a general anemia claim. Anemia caused by cancer, chemotherapy, inflammatory disease, nutritional deficiency, or blood loss would not satisfy the renal-disease limitation unless renal disease is also causally associated with the treated anemia.
Treatment scope
The claims are not dose-specific or regimen-specific. A low-dose or intermittent regimen could potentially fall within the claim if it is administered with the purpose of treating the claimed condition. The absence of an efficacy threshold limits the usefulness of a noninfringement position based only on the magnitude of hemoglobin response.
What patent rights are not covered by US 8,557,834?
The provided claims do not cover several commercially important categories.
| Rights category |
Covered by the provided claims? |
Analysis |
| Composition of matter |
No |
The claims recite administration, not ownership of the molecule itself. |
| Pharmaceutical composition |
No |
No excipient, dosage form, or composition limitation appears. |
| Oral tablet |
No |
Route and dosage form are absent. |
| Extended-release formulation |
No |
No release profile or formulation feature is claimed. |
| Polymorph or crystal form |
No |
Solid-state characteristics are absent. |
| Manufacturing process |
No |
No synthetic step or process condition is recited. |
| Renal anemia method |
Yes |
This is the central claim category. |
| Salt use |
Yes |
Claim 2 expressly includes pharmaceutically acceptable salts. |
| Nonrenal anemia |
No |
The renal-disease association is required. |
| Veterinary treatment |
No |
The claims require a human. |
| Diagnostic method |
No |
No diagnostic step is recited. |
A freedom-to-operate review therefore cannot stop with US 8,557,834. A competitor may avoid these claims by using a different molecule, but it could still face separate composition or formulation patents covering that molecule.
When does US 8,557,834 lose exclusivity?
The statutory term for a modern US patent generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and other term effects under 35 U.S.C. §§ 154 and 156.
The grant date, October 15, 2013, does not determine expiration. The controlling analysis requires the patent’s priority chain, application filing data, patent-term adjustment, and any terminal disclaimer recorded by the USPTO.
| Exclusivity issue |
Relevance to US 8,557,834 |
| Patent term |
Based principally on the earliest effective nonprovisional filing date |
| Patent-term adjustment |
May extend the ordinary term |
| Patent-term extension under 35 U.S.C. § 156 |
Generally tied to regulatory review of an approved product; no FDA-approved FG-2216 product is identified |
| Regulatory exclusivity |
No FDA approval-based exclusivity is identified |
| Continuation practice |
Related continuation or divisional patents may have separate claims and expiration dates |
| Terminal disclaimer |
Must be checked in USPTO prosecution records |
| Current enforceability |
Requires confirmation of maintenance-fee status and expiration data |
The patent should therefore be evaluated as part of the entire US FG-2216 family rather than as an isolated grant.
What is the Orange Book status of FG-2216 and US 8,557,834?
FG-2216 does not have an FDA-approved marketed reference product identified in Drugs@FDA or the FDA Orange Book. As a result, US 8,557,834 is not functioning as an Orange Book-listed patent for an approved FG-2216 product.
The consequences are material:
- No ANDA applicant can rely on an FG-2216 reference listed drug that has been approved by FDA.
- No conventional Paragraph IV certification is available against this patent in the absence of an applicable listed drug.
- The patent does not create the standard Hatch-Waxman early-litigation pathway associated with an approved small-molecule product.
- A future sponsor would likely require a new drug application or another applicable FDA pathway rather than an ANDA based on an approved FG-2216 reference product.
A Paragraph IV certification could become relevant only if an FDA-approved product and reference listing eventually existed and the patent were properly listed against that product.
Which companies challenge the patent, and what litigation affects it?
The two claims provided do not identify a litigation settlement, license, or challenger. Because FG-2216 has not been approved as a commercial FDA product, the usual generic litigation pattern involving an ANDA filer and an Orange Book-listed patent is not apparent.
Potential dispute theories would include:
- Noninfringement because the accused compound is not FG-2216.
- Noninfringement because the anemia is not associated with renal disease.
- Lack of human administration.
- Lack of treatment intent.
- Invalidity based on anticipation or obviousness.
- Written-description or enablement challenges.
- Claim construction concerning the exact chemical nomenclature.
- Patent-term or terminal-disclaimer issues.
- Enforceability issues tied to prosecution conduct or maintenance fees.
A commercial program using FG-2216 for chronic kidney disease anemia would face substantially greater risk than a program using a structurally unrelated HIF-PHI for a different indication.
How does this patent compare with competing HIF-PHI patent estates?
US 8,557,834 is narrower than the typical core patent estate for a marketed HIF-PHI.
| HIF-PHI |
Development or commercial status |
Typical estate focus |
| FG-2216 |
Investigational; no FDA-approved product identified |
Compound, HIF-PH inhibition, anemia methods, formulations |
| Roxadustat |
Approved in several jurisdictions; not approved by FDA as of the cited FDA records |
Composition, salts, formulations, anemia methods |
| Vadadustat |
FDA-approved for specified chronic kidney disease anemia use |
Composition, formulation, dosing, treatment methods |
| Daprodustat |
FDA-approved for selected dialysis-dependent CKD anemia use |
Composition, treatment methods, dosing and formulation |
| Molidustat |
Approved in some jurisdictions; regulatory status varies by market |
Composition and renal-anemia treatment |
| Enarodustat |
Approved in Japan |
Composition, dosing, formulation and anemia methods |
The key distinction is that competing HIF-PHI estates generally contain composition-of-matter claims that can block manufacture and sale of the active ingredient. US 8,557,834, based on the provided claims, is a use patent and does not independently establish product-level control over all commercial activity involving FG-2216.
What generic or follow-on launch risks exist?
A conventional generic launch is unlikely without an approved FG-2216 reference product. The more realistic scenarios are:
- Research-use entry: Low direct risk if no therapeutic administration to humans occurs.
- Clinical development of FG-2216: High method-claim risk for renal anemia trials or treatment programs conducted during the enforceable term.
- Commercial use after patent expiration: Method-claim risk falls when the patent expires, subject to other unexpired family rights.
- Alternative HIF-PHI launch: US 8,557,834 is unlikely to block a structurally distinct HIF-PHI by itself.
- Salt or formulation launch: Claim 2 reaches pharmaceutically acceptable salts, but separate formulation and composition patents may create additional barriers.
- Nonrenal indication: The specific claims may not reach a nonrenal indication, although other patents could.
How strong is the patent estate represented by US 8,557,834?
The claims have moderate value as a targeted method patent and limited value as a standalone product barrier.
Strengths include:
- A defined renal-anemia indication.
- Human-treatment language.
- No dose or route limitation.
- Express coverage of pharmaceutically acceptable salts.
- Potential relevance to multiple chronic kidney disease populations.
Weaknesses include:
- No composition-of-matter protection in the provided claims.
- No formulation protection.
- No manufacturing protection.
- Dependence on proving renal association and therapeutic use.
- No apparent FDA-approved product supporting an Orange Book strategy.
- Potential expiration or term limitations.
- Potential availability of alternative HIF-PHIs outside the claimed chemical structure.
Key Takeaways
- US 8,557,834 is a narrow method-of-treatment patent for FG-2216 in human renal-disease-associated anemia.
- Claim 1 covers the specified free compound; Claim 2 extends coverage to the compound and pharmaceutically acceptable salts.
- The claims do not cover a broad HIF-PHI class, pharmaceutical formulations, polymorphs, or manufacturing processes.
- No dose, route, treatment duration, dialysis status, or hemoglobin threshold is required.
- FG-2216 has no identified FDA-approved reference product, so the patent does not support a conventional Orange Book Paragraph IV challenge.
- Competitors using structurally different HIF-PHIs are not ordinarily captured by these claims.
- The patent’s commercial importance depends on the full family, including composition, formulation, process, continuation, and foreign rights.
- Exact loss-of-exclusivity analysis requires the recorded USPTO priority chain, patent-term adjustment, terminal disclaimers, and maintenance status.
FAQs About US Patent 8,557,834 and FG-2216
Is US 8,557,834 a composition-of-matter patent?
No. The provided claims are method claims requiring administration of FG-2216 to a human for renal-disease-associated anemia.
Does Claim 2 cover a prodrug of FG-2216?
Not automatically. A prodrug generally has a different chemical structure and would need to fall within the claim’s interpretation of the specified compound or salt. Claim 2 expressly addresses pharmaceutically acceptable salts, not all prodrugs.
Can a different HIF-PH inhibitor infringe US 8,557,834?
Ordinarily no, if the competing active ingredient is structurally different from the specifically recited FG-2216 molecule. Other patents may still cover the competing HIF-PHI.
Does the patent cover treatment of anemia in dialysis patients?
Potentially, if the anemia is associated with renal disease and FG-2216 is administered to a human. The claims do not exclude dialysis patients or require a specific dialysis status.
Does FDA approval of another HIF-PHI affect US 8,557,834?
No. Approval of roxadustat, vadadustat, daprodustat, or another HIF-PHI does not by itself expand the chemical scope of US 8,557,834. Each product must be evaluated against its own patent and regulatory estate.
References
- United States Patent and Trademark Office. (2013). United States Patent No. 8,557,834, methods of treating anemia.
- United States Code. (2023). 35 U.S.C. §§ 154-156: Patent term and patent-term adjustment or extension.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
- U.S. Food and Drug Administration. (2023). Approved drug product with therapeutic equivalence evaluations, 43rd edition.